Aurora Cannabis Inc. produces and distributes medical cannabis products globally. The company is headquartered in Edmonton, Canada.
| Revenue (TTM) | $320.59M |
| Gross Profit (TTM) | $136.65M |
| EBITDA | $-32.96M |
| Operating Margin | -26.40% |
| Return on Equity | -10.50% |
| Return on Assets | -4.01% |
| Revenue/Share (TTM) | $5.65 |
| Book Value | $6.12 |
| Price-to-Book | 0.46 |
| Price-to-Sales (TTM) | 0.51 |
| EV/Revenue | 0.436 |
| EV/EBITDA | 15.32 |
| Quarterly Earnings Growth (YoY) | -94.70% |
| Quarterly Revenue Growth (YoY) | 5.10% |
| Shares Outstanding | $61.94M |
| Float | $61.54M |
| % Insiders | 1.27% |
| % Institutions | 9.70% |
Volatility is currently contracting
Aurora Cannabis' shares plunge 28% in three months as a cautious fiscal 2027 outlook overshadows record medical cannabis growth and global expansion.
NASDAQ | TSX: ACB The Company makes history as the first and only cannabis company to ever receive this recognition EDMONTON, AB, July 9, 2026 /PRNewswire/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB) ("Aurora" or the "Company"), the Canadian-based leading global medical cannabis company, has been awarded on TIME Canada's Best Companies 2026 list. This win reflects the Company's differentiated performance and commitment to industry excellence.
Shareholders are encouraged to keep an eye out for their meeting materials and vote early – every vote matters, no matter how many shares you own. Shareholders who have questions or need assistance with voting their shares voting should contact Aurora's strategic advisor and proxy solicitation agent, Kingsdale Advisors by telephone at 1-800-749-9052 or by email at contactus@kingsdaleadvisors.com or visit www.MyAuroraVote.com EDMONTON, AB, July 8, 2026 /PRNewswire/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (TSX: ACB) (NASDAQ: ACB), a leading Canada-based global medical cannabis company, is pleased to announce that the management information circular (the "Circular") for the upcoming annual general meeting of shareholders is now available on the Company's website at www.auroramj.com/investors/corporate-governance as well as under its profile on SEDAR+ (www.sedarplus.ca).
ACB frames fiscal 2027 as a reset year as Canadian reimbursement pressure weighs on margins, even as global medical cannabis growth continues.
Aurora Cannabis reported Q4/FY2026 results largely in line with expectations previously outlined by management. In recent months, the company has made the strategic decision to exit its lower margin consumer cannabis and plant propagation operations and focus on the growing European medical cannabis market. However, FY2027 will be impacted by adverse regulatory changes in the Canadian medical cannabis market. As a result, sales and margins are expected to decline quite meaningfully this year.
Aurora Cannabis NASDAQ: ACB reported a stronger fiscal 2026 performance than it had forecast, driven by growth in global medical cannabis, while warning that fiscal 2027 will be a “reset year” as Canadian medical reimbursement changes weigh on revenue and margins.
NASDAQ | TSX: ACB Achieves Record Annual Global Medical Cannabis Net Revenue1 of $288.6 million, representing 18% YoY growth Delivers Record Annual Adjusted EBITDA 1 of $53.8 million, representing 32% YoY growth Completes Accretive Acquisition of Safari Flower Company in April, an established EU-GMP Manufacturer, adding Critical Capacity to Serve Growing Profitable International Markets Maintains Strong Balance Sheet with ~$164.7 million of Cash, Short Term Investments and Cash Equivalents2 with no Debt EDMONTON, AB, June 11, 2026 /PRNewswire/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), a leading Canada-based global medical cannabis company, today announced its financial and operational results for the fourth quarter and fiscal year 2026 periods ending March 31, 2026. "During fiscal year 2026, we exceeded our projection for global medical cannabis net revenue1 led by double-digit growth in Europe and delivered on our expectation for Adjusted EBITDA1 with both at record outcomes.
NASDAQ | TSX: ACB From global leadership to local impact, Aurora continues to support Veteran-focused programs across Canada, addressing food security, mental health, and community engagement EDMONTON, AB, June 2, 2026 /PRNewswire/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian-based leading global medical cannabis company, shares recent contributions through its Strains for Heroes program, expanding support for Veteran communities across Canada. Aurora's ongoing commitment to support Veterans includes five per cent of net profits from the sale of Strains for Heroes products being donated annually to veteran-focused organizations, up to a maximum of C$200,000.
NASDAQ | TSX: ACB EDMONTON, AB, May 28, 2026 /PRNewswire/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), the Canadian based leading global medical cannabis company, announced today that it has scheduled a conference call to discuss the results for its fourth quarter and fiscal year 2026 on Thursday, June 11, 2026 at 8:00 a.m. Eastern Time | 6:00 a.m.
Many marijuana stock investors have a strong positive outlook on the future of the market. If you've been watching the cannabis sector, then you know how volatile and uncertain trading can be. Yet there have been changes that give more upside to what the future of investing can hold. As cannabis is now a class 3 substance federally, more companies are making shifts in their business to get in line with this new legislation.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on ACB and any ticker you trade — then tracks every position and per-strategy win rate.
